Transparency: EMA rejects Abbvie copyright claims, mulls InterMune patent ploy
This article was originally published in Scrip
Executive Summary
In trying to prevent the European Medicines Agency from releasing clinical trial data on its blockbuster product Humira (adalimumab), Abbvie is claiming not only that the documents in question are commercially confidential, but that releasing them would be a breach of copyright law.